IndustryCompany release

CareDx lifts 2026 guidance after Naveris deal helps third-quarter revenue reach $139 million

🇺🇸 CareDx, Inc. (CDNA) · Thu 29 Oct 2026

The transplant diagnostics company reported GAAP net income of $19 million for Q3 and said its AlloHeme test remains on track for a planned launch in the first quarter of 2027.

CareDx reported results for the third quarter of 2026, covering the period ended 30 September, with revenue of $139 million. The company's headline description put the increase at 39%.

The quarter included the contribution of Naveris and its NavDx test, an acquisition that closed on 1 July. CareDx, which describes itself as a transplant, oncology and cell therapy diagnostics company, also posted GAAP net income of $19 million for the period.

On the back of the results, CareDx raised its full-year 2026 outlook. It now expects revenue of $520 million to $530 million and adjusted EBITDA of $90 million to $100 million.

The company also said its AlloHeme product is on track for a planned launch in the first quarter of 2027. The summary provided does not give further detail on the product, its intended use or any regulatory pathway.

What it means for your team

  • The Naveris/NavDx acquisition is now part of CareDx's reported revenue, so oncology diagnostics are a larger share of the company's portfolio.
  • Teams tracking AlloHeme should note the planned Q1 2027 launch timing; no regulatory or reimbursement details were included in the material available.
  • Market-access professionals may want to watch how the raised 2026 guidance of $520-530 million in revenue shapes the company's commercial priorities.

Company's press release (SEC filing): CareDx, Inc. ↗

Article written by VigiEye from the official source (CareDx, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →